This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Memory Training Intervention for Breast Cancer Survivors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Diane Von Ah, Indiana University
ClinicalTrials.gov Identifier:
NCT01497015
First received: December 15, 2011
Last updated: April 11, 2017
Last verified: April 2017
  Purpose

This is a randomized controlled trial to evaluate the ACTIVE memory training intervention and ACTIVE speed of processing training to waitlist, no-contact control conditions. Specific aims and hypotheses are:

Aim 1: Evaluate the acceptability and usefulness of the ACTIVE memory intervention among Breast Cancer Survivors (BCS).

Hypothesis 1: BCS assigned to the memory intervention arm will perceive the intervention as more acceptable and useful than BCS assigned to the attention control condition.

Aim 2: Establish preliminary efficacy of the ACTIVE memory training intervention relative to the attention control and no-contact control conditions.

Hypothesis 2: Memory training will result in greater memory enhancement immediately post and 2-months post-intervention relative to attention control or no-contact control conditions.


Condition Intervention
Breast Cancer Behavioral: memory training Behavioral: speed of processing training Behavioral: waitlist control

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Supportive Care
Official Title: Memory Training Intervention for Breast Cancer Survivors

Resource links provided by NLM:


Further study details as provided by Diane Von Ah, Indiana University:

Primary Outcome Measures:
  • Memory Performance [ Time Frame: Baseline, immediately post intervention ]
    Evaluate the acceptability and usefulness of the ACTIVE memory intervention among Breast Cancer Survivors.

  • Memory Performance [ Time Frame: 2-month post intervention ]
    Evaluate the acceptability and usefulness of the ACTIVE memory intervention among Breast Cancer Survivors.


Secondary Outcome Measures:
  • Subjective Cognitive Function [ Time Frame: baseline, immediately post intervention ]
    Preliminary efficacy established by objective neuropsychological tests and quality of life.

  • Subjective Cognitive Function [ Time Frame: 2-month follow-up ]
    Post intervention efficacy established by objective neuropsychological tests and quality of life.

  • Symptom distress [ Time Frame: baseline, immediately post intervention ]
    Preliminary symptom distress

  • Symptom distress [ Time Frame: 2-month follow-up ]
    Post intervention symptom distress

  • Quality of life [ Time Frame: baseline, immediately post intervention ]
    Quality of life cancer survivors is a 66 item instrument used to measure QOL in this sample. Means and frequencies were aggregately analyzed.

  • Quality of life [ Time Frame: 2-month follow-up ]
    Quality of life cancer survivors is a 66 item instrument used to measure QOL in this sample. Means and frequencies were aggregately analyzed.


Enrollment: 88
Study Start Date: September 2008
Study Completion Date: December 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: memory training
memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
Behavioral: memory training
10 1-hour sessions over 6-8 weeks
Experimental: speed of processing training
Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
Behavioral: speed of processing training
10 1-hour sessions delivered over 6-8 weeks
Experimental: waitlist control
Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
Behavioral: waitlist control
Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.

Detailed Description:
Memory deficits are a prevalent, bothersome, and potentially debilitating symptom for millions of breast cancer survivors (BCS). Evidence-based treatment is difficult because there has been little intervention research in this area. Memory training may be a viable treatment option for BCS in need. Therefore, the purpose of this study is to examine the acceptability, usefulness, and preliminary efficacy of the memory training intervention from the Advanced Cognitive Training in Vital Elderly (ACTIVE) trial, the largest controlled trial of cognitive interventions in the behavioral sciences. The memory training intervention will be compared to attention control and no-contact control groups. Specific aims are to (1) evaluate the acceptability and usefulness of the memory intervention in BCS and (2) establish preliminary efficacy of the ACTIVE memory training intervention relative to attention control and no-contact control conditions. Acceptability and usefulness will be assessed through self-report. Memory will be assessed through objective neuropsychological tests. A total of 108 eligible BCS will be randomized to memory training, attention control, or no-contact control. A blinded and trained tester will perform data collection and neuropsychological testing at three time points: baseline prior to the intervention, immediately post-intervention, and 2 months post-intervention. Findings will provide information about the acceptability, usefulness, and preliminary efficacy of the ACTIVE memory training intervention on memory performance in BCS. Positive results will lead to a larger, full-scale study to determine efficacy of memory training interventions for BCS. Nursing interventional research in this area is vital to the development of evidence-based interventions to address memory deficits in BCS.
  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. female gender (breast cancer is rare in men);
  2. self-reported memory impairment and desire for treatment (to focus on BCS in greatest need);
  3. first diagnosis of non-metastatic breast cancer (to control for multiple treatments or brain metastases in women with recurrent or metastatic disease);
  4. ≥ 1 year post-treatment including surgery, radiation, and/or chemotherapy (reduce confounding factors related to acute effects of treatment);32
  5. age ≥ 40 years (our prior studies indicate approximately 75% of BCS meet this criterion and reduce sample variability);
  6. post-menopausal (majority are post-menopausal at diagnosis and reduce sample variability); and
  7. able to read, write, understand, and speak English (to ensure informed consent).

Exclusion Criteria:

Women will be excluded if they have other co-morbidities or deficits that would sufficiently impair performance or inhibit cognitive training including:

  1. substantial cognitive decline (score < 24 on the Mini Mental State Exam (MMSE);33
  2. history of stroke, encephalitis, traumatic brain injury, brain surgery, dementia, Alzheimer disease, or Parkinson disease;
  3. cranial radiation therapy or intrathecal therapy;
  4. current active major depression or substance abuse or history of bipolar disorder, psychosis, schizophrenia, or learning disability;
  5. history of or current other cancer except for basal cell skin cancer; or
  6. receiving other cognitive training (to avoid exposure to other training).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01497015

Locations
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Diane Von Ah, PhD, RN, CNA Indiana University
Study Director: Andrew Saykin, PsyD Indiana University
Study Director: Frederick Unverzagt, PhD Indiana University
Study Director: Janet Carpenter, PhD, RN Indiana University
Study Director: Patrick Monahan, PhD Indiana University
  More Information

Responsible Party: Diane Von Ah, Associate Professor, Department Chair, School of Nursing, Indiana University
ClinicalTrials.gov Identifier: NCT01497015     History of Changes
Other Study ID Numbers: 64194
Study First Received: December 15, 2011
Last Updated: April 11, 2017

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Methamphetamine
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on September 19, 2017